Drug Overview

Guadecitabine (also known by its research code SGI-110) is an investigational “next-generation” hypomethylating agent (HMA). It is a small-molecule, dinucleotide prodrug of decitabine, designed to treat various blood cancers and solid tumors.

Guadecitabine was engineered to overcome the primary limitation of older HMAs (like decitabine and azacitidine): their rapid breakdown in the body. By linking decitabine to deoxyguanosine, guadecitabine creates a “delayed-release” effect. This allows for a more prolonged exposure of the cancer cells to the drug, leading to deeper and more durable epigenetic changes.

Generic Name: Guadecitabine.
Other Names: SGI-110.
Drug Class: Hypomethylating Agent (HMA) / DNA Methyltransferase (DNMT) Inhibitor.
Target: DNA Methyltransferase (DNMT1, DNMT3A, DNMT3B).
Route of Administration: Subcutaneous (SC) injection.
FDA Approval Status: Investigational. As of March 2026, guadecitabine is not FDA-approved. It has been studied extensively in Phase III clinical trials (such as ASTRAL-1 and ASTRAL-2). While it did not reach its primary endpoints in some large-scale trials compared to “investigator’s choice” of therapy, it remains a subject of intense research as an “immune-sensitizer” to be used in combination with other modern immunotherapies.

What Is It and How Does It Work? (Mechanism of Action)

Guadecitabine is an epigenetic modifier. It does not work by killing cells instantly like traditional chemotherapy; instead, it “re-programs” the cancer cell’s DNA to behave like a healthy cell or to become visible to the immune system.

The Problem of DNA Hypermethylation

In many cancers, specifically Acute Myeloid Leukemia (AML), the cell “turns off” its own tumor-suppressor genes by coating them in chemical markers called methyl groups. This process, called hypermethylation, essentially silences the genes that would normally stop the cancer from growing.

Molecular Level Mechanisms

Enzymatic Protection: Guadecitabine is a dinucleotide that is resistant to cytidine deaminase, the enzyme in the liver and gut that normally destroys decitabine. This allows more of the active drug to reach the bone marrow.
DNA Incorporation: Once inside the cell, guadecitabine is slowly metabolized into decitabine and incorporated into the DNA strand during the “S-phase” of the cell cycle (when the cell divides).
DNMT Trapping: Once in the DNA, it acts as a trap for DNA Methyltransferase (DNMT) enzymes. It binds to them irreversibly, preventing them from adding more methyl groups.
Hypomethylation (Gene Re-awakening): As the cell divides, the methyl groups are lost. The previously silenced tumor-suppressor genes are “woken up,” allowing the cell to stop dividing or undergo apoptosis (programmed cell death).
Immune Re-sensitization: Guadecitabine also “turns back on” genes that produce cancer-specific proteins (antigens) on the cell surface, making the cancer much easier for the patient’s immune system to find and attack.

FDA-Approved Clinical Indications

There are currently no FDA-approved indications for guadecitabine.

It is strictly available through participation in clinical trials. Its primary research focus includes:

Relapsed or Refractory Acute Myeloid Leukemia (AML): For patients who have failed prior HMA therapy or intensive chemotherapy.
Myelodysplastic Syndromes (MDS): Investigated as a more potent alternative to azacitidine.
Advanced Solid Tumors: Including ovarian cancer, hepatocellular (liver) carcinoma, and colorectal cancer—often in combination with “checkpoint inhibitors” (like Nivolumab).

Dosage and Administration Protocols

Because guadecitabine is an investigational drug, the dosage is determined by clinical trial protocols. The following reflects the regimen utilized in the pivotal ASTRAL trials.

Treatment Detail	Research Specification
Route	Subcutaneous (SC) injection (typically in the abdomen or thigh).
Dosage	60 mg/m² (calculated based on body surface area).
Schedule	Administered for 5 consecutive days of a 28-day cycle.
Cycle Length	28 days; treatment typically continues as long as the patient shows benefit.
Volume	Delivered in a small, concentrated volume to minimize injection site pain.

Clinical Efficacy and Research Results

Clinical data from 2024 through early 2026 has focused on guadecitabine’s role as a “combination partner.”

AML Results (ASTRAL-1): In a large Phase III trial, guadecitabine showed a Complete Response (CR) rate of roughly 19% in treatment-naive AML patients. While this was similar to other HMAs, the duration of the response was longer in certain genetic subgroups.
Solid Tumor Breakthroughs: 2025 research has shown that guadecitabine can “prime” the tumor microenvironment in ovarian cancer, making tumors that were previously resistant to immunotherapy responsive to PD-1 inhibitors.
MDS/CMML: In patients with Chronic Myelomonocytic Leukemia (CMML), guadecitabine showed significantly higher rates of clinical improvement than older drugs in the same class.

Safety Profile and Side Effects

The side effects of guadecitabine are largely related to its impact on the bone marrow’s ability to produce healthy blood cells.

Common Side Effects (>30%):

Febrile Neutropenia: Fever associated with low white blood cell counts; requires immediate medical attention.
Thrombocytopenia: A drop in platelet counts, increasing the risk of bruising and bleeding.
Anemia: Low red blood cell counts leading to fatigue and shortness of breath.
Injection Site Reactions: Redness, pain, or swelling at the site of the SC injection.

Serious Risks:

Sepsis/Severe Infection: Due to the drug’s effect on the immune system.
Pneumonia: Frequently reported in elderly patients during the first two cycles.
Hepatotoxicity: Transient elevations in liver enzymes, requiring regular blood monitoring.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, guadecitabine is a vital tool for studying “Hematopoietic Stem Cell (HSC) Aging.” Researchers are investigating how DNA methylation causes healthy stem cells to “wear out” over time. By using guadecitabine at very low doses, scientists hope to “rejuvenate” aging stem cells in the bone marrow, potentially improving the body’s natural ability to regenerate blood cells after chemotherapy.

Patient Management and Practical Recommendations

Pre-treatment Tests:

Bone Marrow Biopsy: To establish a baseline of the cancer’s genetic and methylation profile.
CBC with Differential: Required before every cycle to ensure blood counts are high enough for the next dose.
Liver and Kidney Panels: To ensure the body can safely metabolize the drug.

Precautions:

Infection Protection: Patients should be prescribed “prophylactic” (preventative) antibiotics and antifungals during the first few cycles of treatment.
Bleeding Risks: Avoid dental work or minor surgeries during the week of the injections due to low platelet counts.

“Do’s and Don’ts” List:

DO report a fever over 100.4°F (38.8°C) immediately, as it is a medical emergency for HMA patients.
DO rotate the site of the injection (left thigh, right thigh, abdomen) to prevent skin thickening.
DON’T expect an immediate result; HMAs often take 4 to 6 cycles before the full clinical benefit is seen.
DON’T ignore signs of unusual bruising or “petechiae” (tiny red spots on the skin).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Guadecitabine is an investigational agent and is not currently approved by the US FDA for any indication. It is available only through participation in approved clinical trials. Always consult with a qualified hematologist-oncologist regarding your diagnosis and eligibility for research.